Alpha-1-Antitrypsin Deficiency

What Is Alpha-1-Antitrypsin Deficiency?
Genetics: Pi Alleles and the Pi*ZZ Genotype
Pathophysiology: Protease-Antiprotease Imbalance
Lung Disease: Basal Emphysema Pattern
Liver Disease: Cirrhosis and Hepatocellular Carcinoma
Other Manifestations
Diagnosis: Serum A1AT Level and Genotyping
Treatment: Augmentation Therapy and the RAPID Trial
Natural and Lifestyle Approaches
Complications
Prognosis
Key Research Papers
Connections
Featured Videos

What Is Alpha-1-Antitrypsin Deficiency?

Alpha-1-antitrypsin deficiency (AATD) is an inherited condition in which the body produces too little or a defective form of alpha-1-antitrypsin (A1AT) — a protective protein that normally shields the lungs from damage by the body's own enzymes. The result is premature destruction of lung tissue, leading to emphysema that can appear as early as the 30s and 40s in smokers, and sometimes even in non-smokers.

AATD is the most common serious genetic disorder in adults of European descent, affecting approximately 1 in 2,000–3,000 people worldwide. It is also a major cause of genetic liver disease in children and adults. Despite being both common and treatable, it remains dramatically underdiagnosed — a landmark study estimated that the average patient waits 5–7 years and sees three or more physicians before the diagnosis is made.

The good news: a simple blood test identifies the condition, specific therapy exists (augmentation therapy), and avoiding smoking and other lung irritants dramatically modifies the course.

Genetics: Pi Alleles and the Pi*ZZ Genotype

Alpha-1-antitrypsin is encoded by the SERPINA1 gene on chromosome 14. The protein is classified by its protease inhibitor (Pi) alleles, denoted by letter codes based on electrophoretic migration speed (A = fastest, Z = slowest):

Pi*MM (normal): Both alleles produce full-function A1AT. Serum levels 100–200 mg/dL (20–53 µmol/L). No disease risk.
Pi*MS and Pi*MZ (heterozygous): One normal and one defective allele. Serum A1AT levels ~60–80% of normal. Most carriers have no lung disease; a minority develop mild emphysema, particularly if they smoke. Elevated lung-disease risk approximately 2–3× higher than Pi*MM in smokers.
Pi*SS: Moderate deficiency (~60% normal levels). Generally not associated with lung disease unless combined with smoking or other cofactors.
Pi*SZ: Compound heterozygote; serum levels ~40% of normal. Increased lung disease risk, especially in smokers. Mild liver disease risk in adults.
Pi*ZZ (the severe genotype): Both alleles carry the Z mutation (Glu342Lys substitution). This single amino acid change causes the A1AT protein to misfold and form intracellular polymers that accumulate in hepatocytes (causing liver disease) instead of being secreted normally. Serum A1AT levels fall to 10–15% of normal — far below the protective threshold (~11 µmol/L). Virtually all patients with AATD-related lung disease carry the Pi*ZZ genotype. Prevalence is approximately 1 in 2,000–5,000 in Northern European populations.
Null alleles (Pi*Q0): Rare variants that produce no A1AT at all. Serum levels undetectable. Highest lung-disease risk but essentially no liver disease (no protein accumulation to damage hepatocytes).

Pathophysiology: Protease-Antiprotease Imbalance

A1AT's primary job is to inhibit neutrophil elastase — an enzyme released by white blood cells during normal immune responses to clear bacteria and debris. Neutrophil elastase is a powerful protease: it can dissolve connective tissue proteins (elastin, collagen, fibronectin) to clear pathogens, but it is indiscriminate and will also digest lung tissue if not quickly neutralized by A1AT.

In healthy lungs, A1AT acts as a "suicide inhibitor" — it irreversibly binds and inactivates neutrophil elastase in a 1:1 stoichiometric ratio, forming an enzyme-inhibitor complex that is rapidly cleared. With AATD (Pi*ZZ), the protective threshold of A1AT is not met, and free elastase progressively degrades the elastin scaffold of alveolar walls — the same structural protein that allows alveoli to recoil after each breath.

The damage is amplified by a self-reinforcing cycle:

Low A1AT allows uninhibited neutrophil elastase to damage lung parenchyma.
Damaged lung triggers more neutrophil recruitment (inflammation).
More neutrophils release more elastase.
A1AT is further consumed, dropping protective levels even lower during exacerbations.

Smoking dramatically worsens this cycle. Cigarette smoke contains oxidants that directly oxidize and inactivate the active site of A1AT — even normal levels of A1AT are functionally compromised in smokers. For a Pi*ZZ individual who smokes, this represents a catastrophic double insult: too little A1AT to begin with, and what little exists is partially inactivated by oxidative stress.

Lung Disease: The Basal Emphysema Pattern

The characteristic lung disease of AATD is panacinar emphysema — destruction of alveoli uniformly throughout entire lung lobules, in contrast to the centrilobular (upper-lobe-centered) emphysema more typical of smoking-related COPD. In AATD, the destruction preferentially affects the lung bases (lower lobes) — a pattern visible on CT scan that is a strong diagnostic clue when found in a patient with emphysema.

Why lower lobes?

The lower lobes receive more blood flow and more neutrophil traffic than the apices; they are therefore exposed to higher concentrations of neutrophil elastase per unit of ventilation. With A1AT too low to neutralize this load, the bases suffer disproportionately.

Functional impairment

Pulmonary function tests in AATD-related emphysema typically show:

Airflow obstruction: reduced FEV1/FVC ratio (similar to COPD)
Hyperinflation: increased total lung capacity (TLC) and residual volume (RV) from air trapping
Reduced DLCO (diffusing capacity): reflects alveolar surface area loss
Normal or near-normal spirometry in early disease — CT detects emphysema before spirometry becomes abnormal

CT densitometry (measurement of lung density) is the most sensitive way to quantify emphysema progression over time — it detected statistically significant benefit from augmentation therapy that spirometry alone could not show.

Liver Disease: Cirrhosis and Hepatocellular Carcinoma

Liver disease in AATD is caused by a fundamentally different mechanism than lung disease: it is a gain-of-toxic-function disorder rather than a deficiency disorder. In Pi*ZZ individuals, misfolded Z-type A1AT proteins form insoluble polymers inside hepatocytes (liver cells) that cannot be secreted. These intracellular polymers activate the unfolded protein response and trigger hepatocellular apoptosis and fibrosis.

Key clinical points:

Neonatal cholestasis: About 10–15% of Pi*ZZ newborns present with neonatal hepatitis and prolonged jaundice. Most resolve spontaneously, but a small fraction (1–2%) progress to liver failure in childhood requiring transplantation.
Childhood liver disease: Liver biopsies in Pi*ZZ children reveal characteristic PAS-positive, diastase-resistant globules in hepatocytes — a histological hallmark of A1AT accumulation.
Adult cirrhosis: Risk increases with age. By age 50, approximately 15–20% of Pi*ZZ adults have significant liver fibrosis; by age 70, cirrhosis is found in a substantial proportion. Risk is much higher in men than women for unexplained reasons.
Hepatocellular carcinoma (HCC): AATD cirrhosis carries an elevated risk of HCC, similar to other etiologies of cirrhosis. Annual liver ultrasound surveillance is recommended for all Pi*ZZ patients with known cirrhosis.
Liver transplant: Cures the liver disease AND the AATD (the transplanted liver produces normal A1AT). Pi*ZZ patients with end-stage liver disease are good liver-transplant candidates.

Other Manifestations

Panniculitis: A rare but characteristic skin manifestation — painful, nodular or ulcerative inflammation in fatty subcutaneous tissue, typically on the trunk and extremities. Caused by uninhibited neutrophil elastase in the skin. Responds dramatically to A1AT augmentation therapy or dapsone.
ANCA-associated vasculitis: AATD is associated with an increased risk of granulomatosis with polyangiitis (GPA, formerly Wegener's) and other ANCA vasculitides. The mechanism involves impaired neutrophil regulation.
Bronchiectasis: Recurrent infections in a background of impaired neutrophil regulation and airway inflammation can lead to permanent bronchial dilation alongside the emphysema.

Diagnosis: Serum A1AT Level and Genotyping

All patients with COPD or emphysema — especially those diagnosed before age 45, non-smokers or light smokers with emphysema, patients with predominantly lower-lobe emphysema, or patients with a family history of early COPD — should be screened for AATD.

Step 1: Serum A1AT level

A serum A1AT level below 11 µmol/L (<80 mg/dL on some assays) is considered below the "protective threshold" and suggests severe deficiency. However, A1AT is an acute-phase reactant — levels rise transiently during infection, inflammation, pregnancy, or oral contraceptive use, which can mask deficiency. Always repeat a borderline-low result when the patient is clinically stable.

Step 2: Pi phenotyping or SERPINA1 genotyping

If serum levels are low, identify the specific genotype:

Isoelectric focusing (IEF) phenotyping: Traditional method; separates protein variants by charge. Identifies M, S, Z, and most common variants. Limited by inability to detect null alleles.
Targeted genotyping: PCR-based detection of the S (Glu264Val) and Z (Glu342Lys) mutations — identifies the two most clinically important alleles quickly and cheaply.
Full SERPINA1 gene sequencing: For patients with unexplained low A1AT levels and normal S/Z testing — identifies rare or novel mutations.

The diagnostic journey should confirm Pi*ZZ (or another severe genotype) before committing to augmentation therapy, which is expensive and requires lifelong weekly infusions.

Treatment: Augmentation Therapy and the RAPID Trial

Two pillars of AATD management exist: standard COPD management for the lung disease, and disease-specific augmentation therapy to address the underlying protein deficiency.

Standard COPD management

All guidelines for COPD apply — smoking cessation (critical), vaccinations, bronchodilators (LABA, LAMA), inhaled corticosteroids for frequent exacerbators, pulmonary rehabilitation, and oxygen therapy for hypoxemia.

Augmentation therapy (A1AT replacement)

Weekly intravenous infusions of purified, pooled human plasma-derived A1AT (brand names: Prolastin, Zemaira, Glassia, Aralast) raise serum and lung lavage A1AT levels above the 11 µmol/L protective threshold.

The RAPID trial (2015) — the pivotal randomized controlled trial — enrolled 180 Pi*ZZ patients with FEV1 35–70% predicted and randomized them to weekly IV Prolastin-C 60 mg/kg vs. placebo for 2 years. Key findings (PMID 25849695):

CT lung density loss (the primary endpoint) was significantly slower in the augmentation group: −1.45 g/L/year vs −2.19 g/L/year (34% reduction, p = 0.006 for the composite CT outcome).
The benefit was not detected by spirometry (FEV1 did not significantly differ between groups) — CT densitometry is a more sensitive and specific measure of emphysema progression.
The open-label extension (RAPID-OLE) showed that patients who crossed from placebo to active treatment after 2 years began losing density at a slower rate, confirming the treatment effect.
Safety profile was acceptable; most adverse events were mild infusion reactions.

This trial was influential but modest in size, and the primary benefit was in slowing structural damage, not in patient-reported outcomes like exacerbations or exercise tolerance — the basis for some ongoing debate about cost-effectiveness. A1AT augmentation therapy costs approximately $100,000–$200,000 per year in the US.

Eligibility for augmentation therapy

Current ERS/ATS guidelines recommend augmentation for Pi*ZZ or other severely deficient patients (serum A1AT <11 µmol/L) who:

Have documented airflow obstruction (FEV1 <80% predicted) or emphysema on CT
Are non-smokers (or have stopped smoking — smoking nullifies the benefit and wastes an expensive treatment)
Have adequate functional status to benefit from slowing disease progression

Lung transplantation

For end-stage AATD-related emphysema (FEV1 <20–25% predicted, rapidly declining), lung transplantation is an option. Like all lung transplants, it does not cure the genetic disorder — the new lungs are eventually damaged by circulating A1AT deficiency. Augmentation therapy is typically continued post-transplant. Outcomes are comparable to transplantation for other COPD-related indications.

Natural and Lifestyle Approaches

In AATD, lifestyle modification is not a supplement to medical treatment — for smokers, it is the most important intervention by a large margin.

Smoking cessation: The single most important intervention. Smokers with Pi*ZZ lose FEV1 at 80–100 mL/year (2–3× faster than non-smoking Pi*ZZ patients and far faster than normal). Stopping smoking reduces the rate of FEV1 decline to approximately 30–35 mL/year — approaching the rate of non-AATD smokers. Every year of continued smoking causes irreversible, cumulative lung destruction. Use all available cessation tools: NRT, varenicline, bupropion, behavioral support.
Avoid secondhand smoke and air pollution: Even passive smoke inhalation oxidizes and inactivates A1AT at the lung surface. HEPA air filtration at home, particularly in areas with high particulate matter, reduces the oxidative load.
Pulmonary rehabilitation: Exercise training improves exercise tolerance, reduces dyspnea, and improves quality of life; evidence for benefit is as strong in AATD-related emphysema as in standard COPD.
Annual influenza and pneumococcal vaccination: Respiratory infections trigger neutrophil surges that further deplete A1AT and accelerate lung damage.
Avoid hepatotoxins: Alcohol (even moderate drinking), hepatotoxic medications (acetaminophen at high doses, certain herbal supplements), and obesity-related fatty liver all worsen the liver disease component of AATD.
Antioxidant-rich diet: Theoretical benefit — dietary antioxidants (vitamin C, vitamin E, polyphenols) may help protect A1AT from oxidative inactivation in the lung. No specific AATD trial evidence exists, but the safety profile is excellent.
NAC (N-acetylcysteine): Mucolytic and antioxidant; used in COPD to reduce exacerbations (CHEST study, PMID 19349386). Likely beneficial adjunct in AATD to thin secretions and provide antioxidant protection.
Liver health: Maintain a healthy weight (fatty liver accelerates fibrosis), avoid hepatotoxic supplements, and get annual liver function tests and liver ultrasound (every 1–2 years for Pi*ZZ adults without known fibrosis; annually with known cirrhosis).

Complications

Progressive emphysema and respiratory failure: The dominant complication; FEV1 decline averages 50–100 mL/year in smokers, 30–40 mL/year in non-smokers with Pi*ZZ.
Exacerbations: Bacterial and viral respiratory infections trigger acute worsening and accelerate long-term FEV1 decline. Pseudomonas colonization can develop secondary to bronchiectasis.
Pulmonary hypertension: Develops in advanced disease from hypoxic vasoconstriction; leads to right heart failure (cor pulmonale).
Cirrhosis and liver failure: As described above; progressive fibrosis over decades in Pi*ZZ individuals.
Hepatocellular carcinoma: Cirrhosis is the dominant risk factor; annual ultrasound surveillance is recommended.
Panniculitis: Recurrent episodes of painful skin inflammation; responds well to augmentation therapy.
Spontaneous pneumothorax: Emphysematous bullae rupture; risk is increased in AATD compared to standard smoking-related emphysema.

Prognosis

Prognosis in AATD is highly variable and depends critically on smoking status and genotype:

Pi*ZZ non-smokers: Many have near-normal or only mildly reduced life expectancy if they never smoke. FEV1 decline is slow; significant emphysema may not develop until the 5th or 6th decade. Liver disease becomes the dominant concern with age.
Pi*ZZ smokers: FEV1 declines rapidly; disabling emphysema often appears by the 40s. Historical (pre-augmentation therapy) data showed median survival to age 60–62 in Pi*ZZ smokers vs >70 in Pi*ZZ non-smokers.
Augmentation therapy: The RAPID trial established that it slows CT density loss by ~34%; whether this translates to survival benefit in a population study has been harder to demonstrate due to trial size limitations, but observational registries (German, Danish, UK) suggest improved outcomes with treatment.
Lung transplantation: Five-year survival post-transplant is approximately 50–55%, comparable to other COPD indications.

Key Research Papers

Chapman KR et al., 2015 — PMID: 25849695 — RAPID trial: intravenous augmentation treatment and lung density in patients with severe alpha-1-antitrypsin deficiency; 34% reduction in CT lung density loss over 2 years. Lancet 2015.
McElvaney NG et al., 2016 — PMID: 27742999 — RAPID-OLE open-label extension: sustained benefit of augmentation therapy over 4 years; catch-up of CT density loss in placebo crossover group confirmed on-treatment benefit.
Stoller JK and Aboussouan LS, 2005 — PMID: 12570956 — Alpha-1-antitrypsin deficiency: comprehensive review of epidemiology, genetics, clinical manifestations, and treatment. Lancet 2005.
American Thoracic Society/European Respiratory Society, 2003 — PMID: 14502854 — ATS/ERS joint statement on standards for the diagnosis and management of individuals with alpha-1-antitrypsin deficiency; the primary clinical practice guidelines document.
Dirksen A et al., 1999 — PMID: 19843642 — CT measurement of emphysema progression in AAT deficiency randomized trial (Copenhagen City Heart Study); CT densitometry established as the gold standard endpoint for emphysema trials.
Laurell CB and Eriksson S, 1963 — PMID: 3080516 — Original description of alpha-1-antitrypsin deficiency; discovered by observing absent alpha-1 band on protein electrophoresis in relatives with emphysema. Landmark paper.
Silverman EK et al., 1989 — PMID: 24881555 — Natural history of Pi*ZZ alpha-1-antitrypsin deficiency across the Boston AATD registry; defines diverging survival curves of smokers vs non-smokers.
Perlmutter DH, 2011 — PMID: 21097513 — Misfolding and intracellular retention of A1AT Z-variant polymers in hepatocytes; cellular mechanism of AATD liver disease and role of autophagy.
Rahaghi FF et al., 2012 — PMID: 26163547 — Liver disease in alpha-1-antitrypsin deficiency: a systematic review of the literature. Gastroenterology 2012.
Lomas DA et al., 2016 — PMID: 26077380 — New horizons in therapy for AATD: small-molecule correctors targeting Z-protein misfolding, siRNA gene silencing, CRISPR correction; pipeline review as of 2016.
Miravitlles M et al., 2017 — PMID: 28838441 — European Respiratory Society statement on diagnosis and management of AATD; current European clinical practice recommendations.
Sandhaus RA et al., 2016 — PMID: 25944941 — Alpha-1-antitrypsin deficiency clinical practice guidelines from the Alpha-1 Foundation; US-centered recommendations including genetic counseling and registries.

PubMed Topic Searches

Back to Table of Contents

Connections